文献速递乳腺MR

扩散加权成像作为动态对比增强乳腺MRI的补充:能否帮助预测恶性、组织学分级和复发?

The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence?
PubMed 文献 · Acad Radiol · 2018-10-04

该回顾性研究纳入111例患者共156个BI-RADS 4、5或6级乳腺病灶,评估DWI联合ADC图补充DCE-MRI鉴别良恶性、病理亚型及复发风险的价值。恶性病灶平均ADC值显著低于良性病灶(1085±343 vs 1481±276 ×10⁻⁶ mm²/s,AUC=0.82);PR阴性及Oncotype评分≥18的肿瘤ADC值显著更低;ADC值与肿瘤分级及ER/HER2状态无显著相关。

要点

  • 恶性病灶平均ADC值显著低于良性病灶,AUC=0.82,有较高预测价值。
  • PR阴性且Oncotype评分≥18(中高危复发风险)的肿瘤ADC值显著更低。
  • ADC值与肿瘤分级、ER/HER2状态无显著相关性。

核心结论

  • ADC值是鉴别恶性、区分Oncotype评分较高及PR阴性肿瘤的重要因素,可作为辅助适当治疗选择的重要工具。

研究设计与样本

  • 回顾性IRB批准研究,2015年1月至2015年12月连续956例患者行双侧乳腺MRI,111例患者检出156个BI-RADS 4、5或6级病灶;采用B0、B100、B600、B1000的DWI联合DCE-MRI,由两名经过乳腺影像专科培训的放射科医师记录扩散和ADC图像数值,并与组织学、肿瘤分级、激素受体(ER、PR、HER-2)及Oncotype DX评分进行相关性分析,p≤0.05为显著。

关键影像表现/征象

  • 恶性病灶平均ADC值显著低于良性病灶(1085±343×10⁻⁶ vs 1481±276×10⁻⁶ mm²/s),高度预测恶性(AUC=0.82)。
  • B100和B600的信号强度有助于区分良性与浸润性导管癌。

诊断标准与关键数值

  • 恶性病灶平均ADC值1085±343×10⁻⁶ mm²/s vs 良性病灶1481±276×10⁻⁶ mm²/s,AUC=0.82。
  • PR阴性且Oncotype评分≥18(中高危复发风险)的肿瘤ADC值显著更低。
  • ADC值与肿瘤分级及ER/HER2状态无显著相关性。

临床应用与阅片要点

  • ADC值可作为DCE-MRI的补充,辅助鉴别乳腺病灶良恶性。
  • ADC值有助于识别PR阴性及Oncotype评分≥18(中高危复发风险)的肿瘤,辅助治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To evaluate the value of adding Diffusion Weighted Imaging (DWI) with Apparent Diffusion Coefficient (ADC) mapping to dynamic contrast enhanced (DCE-MRI) to distinguish benign from malignant pathology subtypes and tumor recurrence.

METHOD AND MATERIALS: In this retrospective IRB approved study, 956 consecutive patients underwent bilateral breast MRI between 1/2015 and 12/2015, with 156 BIRADS 4, 5, or 6 lesions detected in 111 patients. DWI imaging at B0, B100, B600, B1000 was performed with DCE-MRI. Values for diffusion and ADC images were recorded by two fellowship-trained breast radiologists. Mean ADC and signal intensity (SI) values were correlated with histology, tumor grade, hormone receptors (ER, PR, and HER-2)and Oncotype DX scores, when available. p ≤ 0.05 was considered significant.

RESULTS: Of 156 lesions, there were 59 (38%) benign lesions, 24 (15%) Ductal Carcinoma In-Situ, 47 (30%) Invasive Ductal Carcinoma (IDC), 15 (10%) Invasive Lobular Carcinoma (ILC) and 2 (2%) Mucinous carcinoma (MC), five (5%) mixed IDC and ILC, and four (4%) other, including tubular and rare types of malignancy. Mean ADC values for malignancy were significantly lower than for benign lesions (1085 ± 343 × 10-6 vs 1481 ± 276 × 10-6 mm2/s), which is highly predictive (area under curve = 0.82). In addition, tumors with PR negativity and Oncotype score ≥18 (intermediate to high risk for recurrence) demonstrated significantly lower ADC values. SI at B100 and B600 was helpful in distinguishing benign versus IDC. There was no significant correlation between ADC values and tumor grade or ER/HER2 status.

CONCLUSION: ADC value is important factor in distinguishing malignancy, differentiating tumors with higher Oncotype score, and PR negativity. Therefore, it can be used as an important tool to assist appropriate treatment selection.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Roknsharifi S, Fishman MDC, Agarwal MD, et al. The role of diffusion weighted imaging as supplement to dynamic contrast enhanced breast MRI: Can it help predict malignancy, histologic grade and recurrence? Acad Radiol. 2018. PMID: 30293819. doi:10.1016/j.acra.2018.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。